Atlas Legacy Advisors LLC Takes Position in InMode Ltd. (NASDAQ:INMD)

Atlas Legacy Advisors LLC acquired a new stake in shares of InMode Ltd. (NASDAQ:INMD) during the 4th quarter, HoldingsChannel.com reports. The firm acquired 50,799 shares of the healthcare company’s stock, valued at approximately $848,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. D.A. Davidson & CO. grew its holdings in shares of InMode by 5.7% in the fourth quarter. D.A. Davidson & CO. now owns 43,651 shares of the healthcare company’s stock valued at $729,000 after purchasing an additional 2,373 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of InMode by 14.6% in the fourth quarter. Principal Financial Group Inc. now owns 99,562 shares of the healthcare company’s stock valued at $1,663,000 after purchasing an additional 12,661 shares in the last quarter. Harvey Capital Management Inc. grew its holdings in shares of InMode by 1.4% in the fourth quarter. Harvey Capital Management Inc. now owns 51,490 shares of the healthcare company’s stock valued at $860,000 after purchasing an additional 700 shares in the last quarter. Meritage Portfolio Management grew its holdings in shares of InMode by 12.3% in the fourth quarter. Meritage Portfolio Management now owns 16,575 shares of the healthcare company’s stock valued at $277,000 after purchasing an additional 1,810 shares in the last quarter. Finally, DGS Capital Management LLC grew its holdings in shares of InMode by 129.7% in the fourth quarter. DGS Capital Management LLC now owns 24,704 shares of the healthcare company’s stock valued at $413,000 after purchasing an additional 13,948 shares in the last quarter. Institutional investors own 68.04% of the company’s stock.

InMode Stock Up 1.6 %

NASDAQ INMD opened at $19.11 on Wednesday. The company has a fifty day moving average of $17.35 and a two-hundred day moving average of $17.25. The firm has a market capitalization of $1.33 billion, a price-to-earnings ratio of 8.13 and a beta of 2.13. InMode Ltd. has a 52 week low of $14.87 and a 52 week high of $23.46.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Tuesday, February 4th. Barclays raised their target price on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, InMode has a consensus rating of “Hold” and a consensus price target of $22.25.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.